A Randomized, Placebo Controlled Study of Cannabidiol in Young Adult Cannabis Users
University of Colorado, Denver
Summary
The investigators will study the harm-reducing effect of hemp-derived CBD in non-treatment-seeking emerging adults who use cannabis regularly. The study will use a novel naturalistic cannabis administration approach, which examines ecologically valid cannabis use utilizing a mobile lab setting to assess the effects of the cannabis products the participants regularly use. The investigators will recruit a sample of emerging adults, half of whom primarily use flower products and half of whom primarily use concentrate products. Individuals will be randomly assigned to hemp-derived CBD or placebo.
Description
Emerging adults have the highest prevalence of cannabis use and CUD of any age group. Despite high rates of use and CUD, treatment seeking is relatively uncommon among emerging adults. Those who use cannabis are less confident in their ability to abstain and show higher rates of ambivalence regarding the goal of abstinence than those who use other drugs. Thus, emerging adult cannabis users may be more receptive to non-abstinence or harm reduction approaches. The overarching aim of this proposal is to assess the effects of hemp-derived CBD in emerging adults on harms associated with cannabis us…
Eligibility
- Age range
- 18–25 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Ages 18-25 2. Must have used cannabis flower or concentrates at least five days per week for the past year. 3. Currently not seeking to cut down or stop cannabis use 4. At least two symptoms of a DSM-5 cannabis use disorder Exclusion Criteria: 1. Use of any illicit substance besides alcohol, nicotine, or cannabis (e.g., cocaine, opiates, methamphetamine, MDMA, benzodiazepines, or barbiturates) in the past 60 days, as indicated by self-report and urine toxicology screening at the beginning of each study visit. 2. Alcohol use on 3 or more days per week, and/or \>3 drink…
Interventions
- DrugBroad Spectrum Cannabidiol (bsCBD) 400 mg
Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
- DrugPlacebo
Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
Location
- University of Colorado Anschutz Medical CampusAurora, Colorado